Nasdaq tmdx.
Nov 6, 2023 · Cash was $427.1 million as of September 30, 2023. 2023 Financial Outlook. TransMedics is updating its full year 2023 revenue guidance to be in the range of $222 million to $230 million, which ...
On October 2, 2023, Stephen Gordon, the Chief Financial Officer of TransMedics Group Inc (NASDAQ:TMDX), sold 5,000 shares of the company.This move is part of a larger trend, as over the past year ...ANDOVER, Mass., May 26, 2020 (GLOBE NEWSWIRE) -- TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients ...TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today ...57.37. -0.89. -1.53%. TransMedics Group, Inc. (NASDAQ:TMDX) Q3 2023 Earnings Call Transcript November 6, 2023 Operator: Good afternoon, and welcome to TransMedics Third Quarter 2023 Earnings ...
Amount of cash a business has after it has met its financial obligations such as debt and outstanding payments. 24.73M. -15.13%. Get the latest Inmode Ltd (INMD) real-time quote, historical ...
(RTTNews) - The following are some of the healthcare companies that reported their financial results for the quarter ended June 30, 2022, yesterda... (RTTNews) - The following are some of the healthcare companies that reported their financi...
ANDOVER, Mass., Nov. 11, 2021 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with ...Protagonist Therapeutics, Inc. (NASDAQ:PTGX) is the most popular stock in this table. On the other hand TransMedics Group, Inc. (NASDAQ: TMDX ) is the least popular one with only 3 bullish hedge ...Northwest Bancshares (NASDAQ:NWBI) shares reached a new 52-week high of $15.35 on Friday morning, moving up 1.29%. TransMedics Group (NASDAQ:TMDX) shares were down 0.87% on Friday morning to hit a new 52-week high of $61.30. Clearfield (NASDAQ:CLFD) shares set a new 52-week high of $134.54 on Friday, moving up 3.05%.Nov 7, 2023 · 57.37. -0.89. -1.53%. TransMedics Group, Inc. (NASDAQ:TMDX) Q3 2023 Earnings Call Transcript November 6, 2023 Operator: Good afternoon, and welcome to TransMedics Third Quarter 2023 Earnings ... TransMedics Group (NASDAQ:TMDX) is at the forefront of innovation in the healthcare sphere. They are revolutionizing organ preservation with its trailblazing normothermic machine perfusion technology.
Dec 2, 2023 · Transmedics Group Inc (TMDX) shares have gone up 0.77% during the last six months, with a year-to-date growth rate more than the industry average at 18.70% against 10.30. Yet analysts are ramping up their growth forecast for the fiscal year 2023. Revenue is predicted to grow 90.50% this quarter and then drop -112.50% in the quarter after that.
Jul 22, 2022 · Find the latest SEC Filings data for TransMedics Group, Inc. Common Stock (TMDX) at Nasdaq.com.
That number of contracts represents approximately 220,600 underlying shares, working out to a sizeable 52.8% of TMDX's average daily trading volume over the past month, of 417,510 shares.May 21, 2023 · COGS surged from $9 million in 2020 to $28.2 million in 2022, while operating expenses surged from $43 million in 2020 to $96.7 million in 2022. However, there's some good news in terms of the ... ANDOVER, Mass., April 21, 2022 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with ...Dec 1, 2023 · Earnings for TransMedics Group are expected to decrease in the coming year, from ($0.34) to ($0.67) per share. TransMedics Group has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, February 28th, 2024 based off prior year's report dates. Read More. Exchange Traded Funds. ETF Home. Nasdaq Listed ETPs and their DLPs. MQP SEC Approval Order. Nasdaq Indexes and ETFs. Nasdaq-Listed Exchange …TransMedics Group, Inc. (NASDAQ:TMDX) is a Massachusetts-based commercial-stage medical technology company, engaged in transforming organ transplant therapy for end-stage organ failure patients in ...
Nov 24, 2023 · TransMedics Group, Inc. (NASDAQ:TMDX) posted its quarterly earnings data on Monday, November, 6th. The company reported ($0.12) EPS for the quarter, beating the consensus estimate of ($0.18) by $0.06. The business earned $66.43 million during the quarter, compared to analysts' expectations of $48.05 million. This medical technology company is expected to post quarterly loss of $0.26 per share in its upcoming report, which represents a year-over-year change of +31.6%. Revenues are expected to be $32.59 ...TransMedics Group, Inc. (NASDAQ:TMDX) jumped 12.2% to $28.08. The company recently announced the FDA advisory committee panel voted 12 to 5 that the benefits of the OCS Heart System outweigh the ...ANDOVER, Mass., June 03, 2019 (GLOBE NEWSWIRE) -- TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for ...ANDOVER, Mass., Nov. 3, 2023 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that on November 1, 2023, TransMedics granted non-qualified stock options to purchase an …TransMedics Group, Inc. (NASDAQ:TMDX) is a Massachusetts-based commercial-stage medical technology company, engaged in transforming organ transplant therapy for end-stage organ failure patients in ...
ANDOVER, Mass., Feb. 2, 2023 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX ), a medical technology company that is transforming organ transplant therapy for patients with ...
276,036. 5.445315. Back to TMDX Overview. NASDAQ, Inc. short interest is available by issuer for the past 12 months and updated twice a month. Short interest data is reported on mid-month and end ...Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Take-Two Interactive Software, Inc. (Symbol: TTWO), where a total of 15,456 contracts ...TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today ...ANDOVER, Mass., July 26, 2023 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with ...TransMedics Group, Inc. (TMDX) Stock Price | Stock Quote Nasdaq - MarketScreener TRANSMEDICS GROUP, INC. PDF Report TransMedics Group, Inc. Stock price …01:59 PM ET 11/30/2023. Recent sentiment around Nvidia ( NVDA) stock is pointing to signs the stock is set for consolidation. But Dow Jones Industrial Average component …TipRanks | Stock Market Research, News and Analyst Forecasts - TipRanks.comTransMedics Group, Inc. (NASDAQ:TMDX) is a Massachusetts-based commercial-stage medical technology company, engaged in transforming organ transplant therapy for end-stage organ failure patients in ...TransMedics Group, Inc. (NASDAQ:TMDX) is a Massachusetts-based commercial-stage medical technology company, engaged in transforming organ transplant therapy for end-stage organ failure patients in ...ANDOVER, Mass. , Aug. 3, 2023 /PRNewswire/ -- TransMedics Group, Inc. (" TransMedics ") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today... Net revenue of $52.5 million in the second quarter of 2023, a 156% increase compared to the second ...
Apr 23, 2023 · Fintel reports that on May 2, 2023, Oppenheimer maintained coverage of Transmedics Group (NASDAQ:TMDX) with a Outperform recommendation.. Analyst Price Forecast Suggests 8.75% Upside. As of April ...
LivaNova (NASDAQ:LIVN) and TransMedics Group (NASDAQ:TMDX) are both mid-cap medical companies, but which is the superior business?We will compare the two companies based on the strength of their analyst recommendations, community ranking, profitability, institutional ownership, valuation, dividends, risk, media sentiment and earnings.
TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today ...ANDOVER, Mass., Nov. 11, 2021 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with ...NASDAQ: TMDX TransMedics Group. Market Cap. $2B. Today's Change (2.92%) $1.95. Current Price. $68.70. Price as of November 17, 2023, 4:00 p.m. ET. ... (TMDX 2.92%). This high-growth stock has been ...10 Jun, 2021, 10:35 ET. ANDOVER, Mass., June 10, 2021 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX ), a medical technology company that is transforming organ transplant ...ANDOVER, Mass., March 17, 2020 (GLOBE NEWSWIRE) -- TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for ...ANDOVER, Mass., July 30, 2019 (GLOBE NEWSWIRE) -- TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for ...On October 2, 2023, Stephen Gordon, the Chief Financial Officer of TransMedics Group Inc (NASDAQ:TMDX), sold 5,000 shares of the company.This move is part of a larger trend, as over the past year ...Find the latest dividend history for TransMedics Group, Inc. Common Stock (TMDX) at Nasdaq.com.Apr 19, 2022 · ANDOVER, Mass., April 19, 2022 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with ...
With a market capitalization of US$477m, TransMedics Group is a small cap stock, so it might not be well known by many institutional investors. Taking a look at our data on the ownership groups ...ANDOVER, Mass., Feb. 23, 2022 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with ...२०२३ अगस्ट २ ... (“TransMedics”) (Nasdaq: TMDX), a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ ...Instagram:https://instagram. nasdaq rxrxtexas etfwagonierfree alternatives to turbotax ANDOVER, Mass., Nov. 6, 2023 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today reported financial results for the quarter ended September 30, 2023.ANDOVER, Mass., July 30, 2019 (GLOBE NEWSWIRE) -- TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for ... stock insiderlegal insurance companies TMDX’s goal is to have 10-15 planes by operation in H1-24, and each plane typically costs $10-$12m (TMDX does not plan to lease the planes), so you could be potentially looking at capital costs ... dxj Sep 15, 2022 04:05PM EDT. Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in TransMedics Group Inc (Symbol: TMDX), where a total of 2,484 ...In recent trading, shares of TransMedics Group Inc (Symbol: TMDX) have crossed above the average analyst 12-month target price of $78.60, changing hands for $79.05/share. When a stock reaches the ...The latest price target for . TransMedics Gr (NASDAQ: TMDX) was reported by JP Morgan on Tuesday, November 7, 2023.The analyst firm set a price target for 70.00 expecting TMDX to fall to within 12 ...